Drug intelligence / Profile preview

F-15599

Development stage: Preclinical
Lead developer: Neurolixis
Modality: Small Molecules
Administration: Oral

Overview

F-15599 (also known as NLX-101) is a potent and highly selective small molecule agonist of the serotonin 5-HT1A receptor. It exhibits functional selectivity (biased agonism), preferentially activating postsynaptic 5-HT1A receptors in the prefrontal cortex over somatodendritic autoreceptors. This pharmacological profile is thought to offer therapeutic advantages for mood disorders by enhancing antidepressant effects while minimizing typical serotonergic side effects. F-15599 has been investigated for potential use in treating depression, schizophrenia, cognitive disorders, Rett syndrome, and fragile X syndrome[1][2][4][5][6]. The compound was developed by Neurolixis[4].

Other names: F-15,599

Targets

HTR1A (Serotonin receptor 1A (5-hydroxytryptamine receptor 1A))

Beyond the preview

Go deeper on F-15599.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on F-15599.

Explore the full profile